Statistically significant and clinically meaningful reduction in the risk of death seen with Blenrep (belantamab mafodotin) plus bortezomib and dexamethasone (BorDex) versus daratumumab plus BorDex
Real-world and long-term extension data, including updated results from post-launch evaluation of REMS Program, bolster growing body of evidence supporting the efficacy and safety profile of CAMZYOS
Emraclidine was well-tolerated with an adverse event profile consistent with Phase 1b trial
JB’s domestic business continued to out-perform the market with all our major brands posting strong growth
ISB 2001 demonstrated a favorable safety and tolerability profile, and an overall response rate (ORR) of 75% in r/r MM
The workshop aimed to equip medicos with the necessary skills & knowledge to leverage AI's transformative power
Silica is a proven and highly effective anti-caking agent that has been used for decades
Company receives acceptability, in principle, for ZyVac TCV making it eligible for purchase by United Nations procurement agencies
This partnership will enable healthcare organizations to provide best-in-class patient/consumer experiences
The proceeds from its fresh issuance to the extent of Rs 107 crore will be utilized for funding the capital expenditure requirements
Subscribe To Our Newsletter & Stay Updated
